Alnylam Pharmaceuticals, Inc. Stock price
Equities
ALNY
US02043Q1076
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
149.4 USD | -3.20% | +1.93% | -21.92% |
Financials (USD)
Sales 2024 * | 1.84B | Sales 2025 * | 2.26B | Capitalization | 18.82B |
---|---|---|---|---|---|
Net income 2024 * | -524M | Net income 2025 * | -245M | EV / Sales 2024 * | 10.1 x |
Net cash position 2024 * | 191M | Net cash position 2025 * | 563M | EV / Sales 2025 * | 8.07 x |
P/E ratio 2024 * |
-35.8
x | P/E ratio 2025 * |
-85.4
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.6% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | -3.20% | ||
1 week | +1.93% | ||
Current month | -1.09% | ||
1 month | -3.72% | ||
3 months | -23.64% | ||
6 months | -14.12% | ||
Current year | -21.92% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | -.--% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 149.4 | -3.20% | 666,592 |
24-03-27 | 154.4 | +1.59% | 463,043 |
24-03-26 | 152 | -0.07% | 532,485 |
24-03-25 | 152.1 | +3.79% | 799,298 |
24-03-22 | 146.5 | -0.08% | 834,175 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.92% | 18.82B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B | |
-8.77% | 11.06B |